FindTrial
Sign In

5-FU/LV

DRUG5 trials

Sponsors

National Taiwan University Hospital, Hoffmann-La Roche, Changhoon Yoo, Federation Francophone de Cancerologie Digestive, Fundación de investigación HM

Conditions

Colorectal CancerLocally Advanced Rectal Cancer (LARC)Metastatic Biliary Tract CancerMetastatic Pancreatic CancerPancreatic Adenocarcinoma

Phase 1

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma
CompletedNCT00154791
National Taiwan University HospitalPancreatic Adenocarcinoma
Start: 2003-03-31End: 2005-08-31Target: 45Updated: 2005-09-12

Phase 2

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
CompletedNCT02291289
Hoffmann-La RocheColorectal Cancer
Start: 2015-04-17End: 2021-03-24Updated: 2024-05-06
Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer
CompletedNCT03524508
Changhoon YooMetastatic Biliary Tract Cancer
Start: 2018-09-04End: 2021-12-31Updated: 2022-08-24
First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI
CompletedNCT03693677
Federation Francophone de Cancerologie DigestiveMetastatic Pancreatic Cancer
Start: 2018-11-16End: 2025-01-10Updated: 2025-07-01
A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer
CompletedNCT04009876
Fundación de investigación HMLocally Advanced Rectal Cancer (LARC)
Start: 2019-05-01End: 2022-10-21Updated: 2022-12-13

Related Papers

5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61).
Journal of Clinical Oncology2025-05-281 citations
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials.
2025-03-253 citations
Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials.
2024-10-17
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
JAMA Oncology2023-03-2371 citations
Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer
European Journal of Cancer2023-02-0319 citations
Phase II, multicenter, open-label, non-randomized study of neoadjuvant chemotherapy NALIRINOX (5-FU/LV + oxaliplatin + nal-IRI) followed by chemoradiotherapy in patients with rectal cancer in a watch-and-wait program.
Journal of Clinical Oncology2022-06-01
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.
2021-10-14154 citations
A Long-Term Extension Study of Bevacizumab in Patients With Solid Tumors
The Oncologist2021-09-0918 citations
Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).
Journal of Clinical Oncology2021-05-2027 citations
Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAF<sup>wt</sup> metastatic colorectal cancer.
Journal of Clinical Oncology2021-05-204 citations
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
2020-08-3123 citations